Market Closed -
Nasdaq
04:00:00 2024-05-10 pm EDT
|
5-day change
|
1st Jan Change
|
39.08
USD
|
-0.99%
|
|
-6.89%
|
-22.75%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
8,497
|
7,906
|
4,297
|
5,365
|
7,258
|
5,700
|
-
|
-
|
Enterprise Value (EV)
1 |
8,602
|
8,047
|
4,649
|
4,561
|
6,157
|
5,133
|
6,018
|
5,700
|
P/E ratio
|
29
x
|
-17.5
x
|
-152
x
|
-19.9
x
|
-19.8
x
|
-10.3
x
|
-11.2
x
|
-18
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
7.57
x
|
10.8
x
|
5.3
x
|
9.14
x
|
9.21
x
|
9.54
x
|
7.42
x
|
5.42
x
|
EV / Revenue
|
7.66
x
|
11
x
|
5.74
x
|
7.77
x
|
7.81
x
|
8.59
x
|
7.84
x
|
5.42
x
|
EV / EBITDA
|
22.7
x
|
-50.7
x
|
35.6
x
|
-11.5
x
|
-18
x
|
-9.42
x
|
-10.7
x
|
-21
x
|
EV / FCF
|
27.3
x
|
10.4
x
|
247
x
|
-15.7
x
|
-18.6
x
|
-11.2
x
|
-11.1
x
|
-15.8
x
|
FCF Yield
|
3.66%
|
9.59%
|
0.41%
|
-6.36%
|
-5.38%
|
-8.97%
|
-9.05%
|
-6.34%
|
Price to Book
|
5.12
x
|
9.39
x
|
5.57
x
|
9.37
x
|
18.9
x
|
-92.1
x
|
-12.1
x
|
-9.06
x
|
Nbr of stocks (in thousands)
|
140,663
|
139,823
|
141,210
|
142,050
|
143,472
|
145,846
|
-
|
-
|
Reference price
2 |
60.41
|
56.54
|
30.43
|
37.77
|
50.59
|
39.08
|
39.08
|
39.08
|
Announcement Date
|
2/26/20
|
2/24/21
|
2/24/22
|
2/22/23
|
2/21/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
1,123
|
729
|
810
|
587
|
788
|
597.6
|
767.8
|
1,052
|
EBITDA
1 |
378.4
|
-158.7
|
130.5
|
-395.9
|
-342.7
|
-545
|
-564
|
-271.2
|
EBIT
1 |
366
|
-172
|
-30
|
-411
|
-353
|
-574.2
|
-505.8
|
-304.5
|
Operating Margin
|
32.59%
|
-23.59%
|
-3.7%
|
-70.02%
|
-44.8%
|
-96.08%
|
-65.87%
|
-28.95%
|
Earnings before Tax (EBT)
1 |
347
|
-170
|
-30
|
-258
|
-334
|
-571.4
|
-548.6
|
-329.4
|
Net income
1 |
294
|
-451
|
-29
|
-270
|
-366
|
-574.7
|
-544
|
-342.7
|
Net margin
|
26.18%
|
-61.87%
|
-3.58%
|
-46%
|
-46.45%
|
-96.16%
|
-70.85%
|
-32.58%
|
EPS
2 |
2.080
|
-3.230
|
-0.2000
|
-1.900
|
-2.560
|
-3.804
|
-3.482
|
-2.175
|
Free Cash Flow
1 |
314.8
|
772
|
18.84
|
-290.1
|
-331.3
|
-460.3
|
-544.4
|
-361.6
|
FCF margin
|
28.03%
|
105.9%
|
2.33%
|
-49.42%
|
-42.05%
|
-77.02%
|
-70.9%
|
-34.38%
|
FCF Conversion (EBITDA)
|
83.19%
|
-
|
14.44%
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
107.08%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/26/20
|
2/24/21
|
2/24/22
|
2/22/23
|
2/21/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
440
|
142
|
134
|
160
|
152
|
131
|
188
|
144
|
325
|
119
|
144.8
|
159
|
173.4
|
138.9
|
176.7
|
EBITDA
1 |
247.8
|
-53.8
|
-81.73
|
-55.34
|
-205
|
-111.4
|
-
|
-140.7
|
-3.456
|
-
|
-117.2
|
-104.1
|
-125.5
|
-
|
-
|
EBIT
1 |
221
|
-57
|
-86
|
-59
|
-208
|
-114
|
-91
|
-143
|
-6
|
-150
|
-148
|
-145.7
|
-142.2
|
-176
|
-126.5
|
Operating Margin
|
50.23%
|
-40.14%
|
-64.18%
|
-36.88%
|
-136.84%
|
-87.02%
|
-48.4%
|
-99.31%
|
-1.85%
|
-126.05%
|
-102.21%
|
-91.63%
|
-82.01%
|
-126.69%
|
-71.59%
|
Earnings before Tax (EBT)
1 |
225
|
-64
|
-103
|
-47
|
-44
|
-113
|
-77
|
-141
|
-3
|
-143
|
-143.1
|
-140.4
|
-142.3
|
-198.8
|
-158.5
|
Net income
1 |
225
|
-65
|
-105
|
-47
|
-52
|
-124
|
-85
|
-147
|
-9
|
-143
|
-141.9
|
-140.5
|
-141.3
|
-199.5
|
-159.2
|
Net margin
|
51.14%
|
-45.77%
|
-78.36%
|
-29.38%
|
-34.21%
|
-94.66%
|
-45.21%
|
-102.08%
|
-2.77%
|
-120.17%
|
-98%
|
-88.38%
|
-81.47%
|
-143.58%
|
-90.09%
|
EPS
2 |
1.410
|
-0.4600
|
-0.7400
|
-0.3300
|
-0.3700
|
-0.8700
|
-0.6000
|
-1.030
|
-0.0600
|
-0.9800
|
-0.9466
|
-0.9478
|
-0.9175
|
-1.259
|
-1.016
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/24/22
|
5/4/22
|
8/9/22
|
11/9/22
|
2/22/23
|
5/3/23
|
8/9/23
|
11/2/23
|
2/21/24
|
5/7/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
104
|
141
|
352
|
-
|
-
|
-
|
318
|
-
|
Net Cash position
1 |
-
|
-
|
-
|
804
|
1,102
|
567
|
-
|
-
|
Leverage (Debt/EBITDA)
|
0.2755
x
|
-0.8912
x
|
2.697
x
|
-
|
-
|
-
|
-0.5638
x
|
-
|
Free Cash Flow
1 |
315
|
772
|
18.8
|
-290
|
-331
|
-460
|
-544
|
-362
|
ROE (net income / shareholders' equity)
|
23.4%
|
-3.88%
|
-3.78%
|
-40.1%
|
-76.3%
|
-230%
|
-568%
|
-528%
|
ROA (Net income/ Total Assets)
|
9.97%
|
-4.4%
|
-1.14%
|
-10.5%
|
-13.3%
|
-23.3%
|
-26.7%
|
-7.84%
|
Assets
1 |
2,949
|
10,245
|
2,536
|
2,575
|
2,760
|
2,466
|
2,037
|
4,371
|
Book Value Per Share
2 |
11.80
|
6.020
|
5.470
|
4.030
|
2.680
|
-0.4200
|
-3.220
|
-4.310
|
Cash Flow per Share
2 |
2.420
|
0.2600
|
0.2200
|
-1.930
|
-2.150
|
-3.050
|
-3.120
|
-
|
Capex
1 |
30.9
|
35.1
|
12
|
15.7
|
23.8
|
23.3
|
25.7
|
29.7
|
Capex / Sales
|
2.75%
|
4.82%
|
1.48%
|
2.68%
|
3.02%
|
3.9%
|
3.34%
|
2.82%
|
Announcement Date
|
2/26/20
|
2/24/21
|
2/24/22
|
2/22/23
|
2/21/24
|
-
|
-
|
-
|
Last Close Price
39.08
USD Average target price
57.95
USD Spread / Average Target +48.28% Consensus |
1st Jan change
|
Capi.
|
---|
| -22.75% | 5.7B | | +17.96% | 44.96B | | +1.17% | 42.65B | | +48.77% | 41.85B | | -4.27% | 29.04B | | +11.42% | 26.08B | | -21.39% | 19.03B | | +4.86% | 12.75B | | +27.29% | 12.06B | | -3.50% | 11.75B |
Other Biotechnology & Medical Research
|